Design Therapeutics (DSGN) Total Non-Current Liabilities (2020 - 2021)

Design Therapeutics (DSGN) reported Total Non-Current Liabilities of $8.8 million for Q3 2021, up 157.8% sequentially from $3.4 million in Q2 2021.

Design Therapeutics (DSGN) Total Non-Current Liabilities (2020 - 2021) Analysis & Trends

Design Therapeutics (DSGN) has 2 years of Total Non-Current Liabilities data on file, last reported at $8.8 million in Q3 2021.

For the quarter ending Q3 2021, Total Non-Current Liabilities changed N/A year-over-year to $8.8 million; the trailing twelve-month figure through Sep 2021 stood at $8.8 million (changed N/A YoY), and the FY2020 full-year result was $2.3 million, changed N/A from the prior year.
Total Non-Current Liabilities improved to $8.8 million in Q3 2021, from $3.4 million in the prior quarter.
In the past five years, Total Non-Current Liabilities ranged from a high of $8.8 million in Q3 2021 to a low of $2.3 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Non-Current Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	4.45 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	110.28 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	1.98 Bn
4	NuCana	279.75 Bn	279.75 Bn	-	949,738.67
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.87 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	7.32 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	40.00 Mn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	746.94 Mn
10	Design Therapeutics	714.48 Mn	491.66 Mn	-	-

Download Data